Utility of BRAF V600E mutation-specific immunohistochemistry in detecting BRAF V600E-Mutated gastrointestinal stromal tumors

Deepa T. Patil, Shuang Ma, Mai Konishi, Paula D. Carver, Marina Pukay, Carol Beadling, Christopher Corless, Brian P. Rubin

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Objectives: As patients with BRAF V600E mutation respond to BRAF inhibitors, it is important to identify these mutations to stratify patients for the appropriate therapy. In this study, we evaluated the utility of a BRAF V600E allele-specific antibody in gastrointestinal stromal tumors (GISTs). Methods: BRAF V600E mutation-specific immunohistochemistry (negative, weak, or moderate/strong expression) and BRAF sequencing were performed on 38 consecutive GISTs diagnosed between January 2013 and April 2014. Results: GISTs from a cohort of 25 men and 13 women (mean age, 61 years; range, 39-88 years) were localized to the stomach (18), small bowel (10), colon (three), rectum (two), and pelvis/omentum (five). Strong and diffuse cytoplasmic BRAF expression was noted in two (5%) of 38 cases, while eight (21%) of 38 cases showed weak staining, and 28 (74%) of 38 cases were negative. Both of the strongly positive cases arose in the stomach, occurring in a 42-year-old and a 47-year-old woman, respectively. The lesions measured 0.8 and 1 cm, showed spindle cell morphology, and had no risk of progressive disease by Miettinen criteria. Both cases showed heterozygous BRAF V600E, while no BRAF mutations were detected in cases with weak or negative BRAF expression. Conclusions: BRAF V600E mutation-specific immunohistochemistry is a highly sensitive and specific method for detecting BRAF-mutated GISTs.

Original languageEnglish (US)
Pages (from-to)782-789
Number of pages8
JournalAmerican Journal of Clinical Pathology
Volume144
Issue number5
DOIs
StatePublished - Nov 1 2015

Fingerprint

Gastrointestinal Stromal Tumors
Immunohistochemistry
Mutation
Stomach
Omentum
Pelvis
Rectum
Colon
Alleles
Staining and Labeling
Antibodies

Keywords

  • BRAF V600E
  • Gastrointestinal stromal tumor
  • Immunohistochemistry

ASJC Scopus subject areas

  • Pathology and Forensic Medicine

Cite this

Utility of BRAF V600E mutation-specific immunohistochemistry in detecting BRAF V600E-Mutated gastrointestinal stromal tumors. / Patil, Deepa T.; Ma, Shuang; Konishi, Mai; Carver, Paula D.; Pukay, Marina; Beadling, Carol; Corless, Christopher; Rubin, Brian P.

In: American Journal of Clinical Pathology, Vol. 144, No. 5, 01.11.2015, p. 782-789.

Research output: Contribution to journalArticle

Patil, Deepa T. ; Ma, Shuang ; Konishi, Mai ; Carver, Paula D. ; Pukay, Marina ; Beadling, Carol ; Corless, Christopher ; Rubin, Brian P. / Utility of BRAF V600E mutation-specific immunohistochemistry in detecting BRAF V600E-Mutated gastrointestinal stromal tumors. In: American Journal of Clinical Pathology. 2015 ; Vol. 144, No. 5. pp. 782-789.
@article{ac605b78883c48f095b99136daad69bd,
title = "Utility of BRAF V600E mutation-specific immunohistochemistry in detecting BRAF V600E-Mutated gastrointestinal stromal tumors",
abstract = "Objectives: As patients with BRAF V600E mutation respond to BRAF inhibitors, it is important to identify these mutations to stratify patients for the appropriate therapy. In this study, we evaluated the utility of a BRAF V600E allele-specific antibody in gastrointestinal stromal tumors (GISTs). Methods: BRAF V600E mutation-specific immunohistochemistry (negative, weak, or moderate/strong expression) and BRAF sequencing were performed on 38 consecutive GISTs diagnosed between January 2013 and April 2014. Results: GISTs from a cohort of 25 men and 13 women (mean age, 61 years; range, 39-88 years) were localized to the stomach (18), small bowel (10), colon (three), rectum (two), and pelvis/omentum (five). Strong and diffuse cytoplasmic BRAF expression was noted in two (5{\%}) of 38 cases, while eight (21{\%}) of 38 cases showed weak staining, and 28 (74{\%}) of 38 cases were negative. Both of the strongly positive cases arose in the stomach, occurring in a 42-year-old and a 47-year-old woman, respectively. The lesions measured 0.8 and 1 cm, showed spindle cell morphology, and had no risk of progressive disease by Miettinen criteria. Both cases showed heterozygous BRAF V600E, while no BRAF mutations were detected in cases with weak or negative BRAF expression. Conclusions: BRAF V600E mutation-specific immunohistochemistry is a highly sensitive and specific method for detecting BRAF-mutated GISTs.",
keywords = "BRAF V600E, Gastrointestinal stromal tumor, Immunohistochemistry",
author = "Patil, {Deepa T.} and Shuang Ma and Mai Konishi and Carver, {Paula D.} and Marina Pukay and Carol Beadling and Christopher Corless and Rubin, {Brian P.}",
year = "2015",
month = "11",
day = "1",
doi = "10.1309/AJCPRK3V2EIIUPQZ",
language = "English (US)",
volume = "144",
pages = "782--789",
journal = "American Journal of Clinical Pathology",
issn = "0002-9173",
publisher = "American Society of Clinical Pathologists",
number = "5",

}

TY - JOUR

T1 - Utility of BRAF V600E mutation-specific immunohistochemistry in detecting BRAF V600E-Mutated gastrointestinal stromal tumors

AU - Patil, Deepa T.

AU - Ma, Shuang

AU - Konishi, Mai

AU - Carver, Paula D.

AU - Pukay, Marina

AU - Beadling, Carol

AU - Corless, Christopher

AU - Rubin, Brian P.

PY - 2015/11/1

Y1 - 2015/11/1

N2 - Objectives: As patients with BRAF V600E mutation respond to BRAF inhibitors, it is important to identify these mutations to stratify patients for the appropriate therapy. In this study, we evaluated the utility of a BRAF V600E allele-specific antibody in gastrointestinal stromal tumors (GISTs). Methods: BRAF V600E mutation-specific immunohistochemistry (negative, weak, or moderate/strong expression) and BRAF sequencing were performed on 38 consecutive GISTs diagnosed between January 2013 and April 2014. Results: GISTs from a cohort of 25 men and 13 women (mean age, 61 years; range, 39-88 years) were localized to the stomach (18), small bowel (10), colon (three), rectum (two), and pelvis/omentum (five). Strong and diffuse cytoplasmic BRAF expression was noted in two (5%) of 38 cases, while eight (21%) of 38 cases showed weak staining, and 28 (74%) of 38 cases were negative. Both of the strongly positive cases arose in the stomach, occurring in a 42-year-old and a 47-year-old woman, respectively. The lesions measured 0.8 and 1 cm, showed spindle cell morphology, and had no risk of progressive disease by Miettinen criteria. Both cases showed heterozygous BRAF V600E, while no BRAF mutations were detected in cases with weak or negative BRAF expression. Conclusions: BRAF V600E mutation-specific immunohistochemistry is a highly sensitive and specific method for detecting BRAF-mutated GISTs.

AB - Objectives: As patients with BRAF V600E mutation respond to BRAF inhibitors, it is important to identify these mutations to stratify patients for the appropriate therapy. In this study, we evaluated the utility of a BRAF V600E allele-specific antibody in gastrointestinal stromal tumors (GISTs). Methods: BRAF V600E mutation-specific immunohistochemistry (negative, weak, or moderate/strong expression) and BRAF sequencing were performed on 38 consecutive GISTs diagnosed between January 2013 and April 2014. Results: GISTs from a cohort of 25 men and 13 women (mean age, 61 years; range, 39-88 years) were localized to the stomach (18), small bowel (10), colon (three), rectum (two), and pelvis/omentum (five). Strong and diffuse cytoplasmic BRAF expression was noted in two (5%) of 38 cases, while eight (21%) of 38 cases showed weak staining, and 28 (74%) of 38 cases were negative. Both of the strongly positive cases arose in the stomach, occurring in a 42-year-old and a 47-year-old woman, respectively. The lesions measured 0.8 and 1 cm, showed spindle cell morphology, and had no risk of progressive disease by Miettinen criteria. Both cases showed heterozygous BRAF V600E, while no BRAF mutations were detected in cases with weak or negative BRAF expression. Conclusions: BRAF V600E mutation-specific immunohistochemistry is a highly sensitive and specific method for detecting BRAF-mutated GISTs.

KW - BRAF V600E

KW - Gastrointestinal stromal tumor

KW - Immunohistochemistry

UR - http://www.scopus.com/inward/record.url?scp=84947983123&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84947983123&partnerID=8YFLogxK

U2 - 10.1309/AJCPRK3V2EIIUPQZ

DO - 10.1309/AJCPRK3V2EIIUPQZ

M3 - Article

C2 - 26486743

AN - SCOPUS:84947983123

VL - 144

SP - 782

EP - 789

JO - American Journal of Clinical Pathology

JF - American Journal of Clinical Pathology

SN - 0002-9173

IS - 5

ER -